$-0.25 EPS Expected for Fate Therapeutics Inc (FATE)

October 28, 2017 – By Dolores Ford

 $ 0.25 EPS Expected for Fate Therapeutics Inc (FATE)
Investors sentiment decreased to 1.43 in 2017 Q2. Its down 4.97, from 6.4 in 2017Q1. It is negative, as 11 investors sold Fate Therapeutics Inc shares while 12 reduced holdings. 19 funds opened positions while 14 raised stakes. 25.76 million shares or 48.07% less from 49.60 million shares in 2017Q1 were reported.
683 Management Ltd Liability reported 588,237 shares. Redmile Gp Ltd holds 0.28% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE) for 1.42 million shares. Bridgeway Cap Mngmt holds 0.01% or 250,000 shares in its portfolio. Retail Bank Of New York Mellon Corporation holds 157,546 shares. Millennium Mngmt Ltd Liability holds 53,614 shares or 0% of its portfolio. Morgan Stanley accumulated 633,944 shares. Wells Fargo And Mn holds 0% of its portfolio in Fate Therapeutics Inc (NASDAQ:FATE) for 253,063 shares. Connor Clark & Lunn Management holds 0% or 63,500 shares. Guggenheim Limited Liability has invested 0% in Fate Therapeutics Inc (NASDAQ:FATE). Deutsche Bancshares Ag owns 43,925 shares or 0% of their US portfolio. Tiaa Cref Invest Mgmt Llc invested 0% in Fate Therapeutics Inc (NASDAQ:FATE). Fmr Ltd Limited Liability Company holds 0% or 4.35M shares in its portfolio. Bnp Paribas Arbitrage reported 0% stake. Jacobs Levy Equity Mngmt Inc has invested 0% in Fate Therapeutics Inc (NASDAQ:FATE). Barclays Public Limited has 0% invested in Fate Therapeutics Inc (NASDAQ:FATE).

Wall Street await Fate Therapeutics Inc (NASDAQ:FATE) to release earnings on November, 6. Analysts forecast earnings per share of $-0.25, up exactly $0.02 or 7.41 % from 2014’s $-0.27 EPS. After posting $-0.23 EPS for the previous quarter, Fate Therapeutics Inc’s analysts now forecast 8.70 % negative EPS growth. The stock increased 6.82% or $0.29 on October 27, reaching $4.54. About 370,551 shares traded or 59.38% up from the average. Fate Therapeutics Inc (NASDAQ:FATE) has risen 166.12% since October 29, 2016 and is uptrending. It has outperformed by 149.42% the S&P500.

Fate Therapeutics Inc (NASDAQ:FATE) Ratings Coverage

Among 8 analysts covering Fate Therapeutics (NASDAQ:FATE), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Fate Therapeutics had 8 analyst reports since October 6, 2015 according to SRatingsIntel. Raymond James initiated Fate Therapeutics Inc (NASDAQ:FATE) on Tuesday, October 6 with “Outperform” rating. The company was initiated on Friday, December 4 by Wells Fargo. As per Tuesday, April 12, the company rating was initiated by BMO Capital Markets. H.C. Wainwright reinitiated Fate Therapeutics Inc (NASDAQ:FATE) rating on Thursday, October 12. H.C. Wainwright has “Buy” rating and $7 target. The rating was initiated by Leerink Swann on Friday, September 8 with “Buy”. On Thursday, September 22 the stock rating was initiated by Roth Capital with “Buy”. The rating was initiated by TH Capital on Thursday, September 22 with “Buy”. The stock of Fate Therapeutics Inc (NASDAQ:FATE) earned “Outperform” rating by Wedbush on Tuesday, November 8.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company has market cap of $188.03 million. The Firm is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. It currently has negative earnings. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.